key: cord-0941080-4xmhhrlm
authors: Wan, Yize I; Bien, Zuzanna; Apea, Vanessa J; Orkin, Chloe M; Dhairyawan, Rageshri; Kirwan, Christopher J; Pearse, Rupert M; Puthucheary, Zudin A; Prowle, John R
title: Acute Kidney Injury in COVID-19: multicentre prospective analysis of registry data
date: 2021-03-27
journal: Clin Kidney J
DOI: 10.1093/ckj/sfab071
sha: b5a801df37a122f993c0dfd1de046cfe63e24ca9
doc_id: 941080
cord_uid: 4xmhhrlm

BACKGROUND: Acute kidney injury (AKI) is a common and important complication of COVID-19. Further characterisation is required to reduce both short and long-term adverse outcomes. METHODS: We examined registry data including adults with confirmed SARS-CoV-2 infection admitted to five London Hospitals from 1(st) January to 14th May 2020. Prior end-stage kidney disease was excluded. Early AKI was defined by Kidney Disease Improving Global Outcomes (KDIGO) creatinine criteria within 7 days of admission. Independent associations of AKI and survival were examined in multivariable analysis. Results are given as odds ratios (OR), or hazard ratios (HR) with 95% confidence intervals. RESULTS: Amongst 1855 admissions, 453 patients (24.5%) developed early AKI: 220 (44.0%) stage 1, 90 (19.8%) stage 2, 165 (36.3%) stage 3 (74 receiving renal replacement therapy). The strongest risk factor for AKI was high CRP (OR 3.35 [2.53-4.47], p < 0.001). Death within 30 days occurred in 242 (53.2%) with AKI compared to 255 (18.2%) without. In multivariable analysis, increasing severity of AKI was incrementally associated with higher mortality: stage 3 (HR 3.93 [3.04-5.08], p < 0.001). In 333 patients with AKI surviving to day 7, 134 (40.2%) recovered, 47 (14.1%) recovered then relapsed, and 152 (45.6%) had persistent AKI at day 7; an additional 105 (8.2%) patients developed AKI after day 7. Persistent AKI was strongly associated with adjusted mortality at 90-days (OR 7.57 [4.50-12.89], p < 0.001). CONCLUSIONS: AKI affected one in four hospital in-patients with COVID-19 and significantly increased mortality. Timing and recovery of COVID-19 AKI is a key determinant of outcome.

Development of acute kidney injury (AKI) appears common in COVID-19, however geographical differences in incidence and severity have been described (1) (2) (3) (4) (5) (6) . In a metaanalysis of 20 cohorts worldwide, overall prevalence during admission was 17% ranging from 0.5% to 80.3% (7) . This variation likely reflects differences in sample sizes and cohort characteristics including in monitoring and detection of AKI (8) . Few studies have reported timing and severity of AKI, or temporal relationships to interventions including renal replacement therapy (RRT) (9) . Short follow-up periods have also limited analysis of longerterm survival and kidney recovery. Importantly, more severe AKI has been strongly and consistently associated with short term risk of death (10, 11) , making AKI a potentially pivotal complication in the deteriorating COVID-19 patient. Better understanding of risk factors involved may enable early recognition and use of preventative and therapeutic measures to limit AKI development or progression reducing overall morbidity and mortality.

The mechanisms involved in kidney damage in COVID-19 are likely to be multifactorial.

These potentially include direct viral effects on the kidney (12, 13) , systemic immune dysregulation, and hypercoagulability (11, 14) as well as traditional risk-factors for primary tubular injury including hypovolaemia, sepsis related haemodynamic instability, and consequences of intensive care unit (ICU) therapies (8, (15) (16) (17) . Patient risk factors for COVID-19 AKI are common to those of AKI in other settings, including older age and comorbid diseases (1, 18) . Importantly while racial and socioeconomic background have been identified as potential risk factors for SARS-CoV-2 infection and adverse outcomes in COVID-19 disease, the influence of these factors on the incidence of COVID-19 associated AKI is unclear despite pre-existing evidence for racial and socioeconomic disparities leading to higher AKI incidence and poorer outcomes outside of COVID-19 (19) . Accordingly, we aimed to define the incidence and severity of AKI during hospital admission, examine trajectories of AKI progression and kidney recovery following hospital discharge, and identify risk factors for AKI and adverse outcomes including the influence of ethnicity and measures of socio-economic status.

We included all patients aged 16 years or over admitted to one of five acute hospitals within Barts Health NHS Trust between 1st January and 13th May 2020 with SARS-CoV-2 infection confirmed on PCR (20) . The first emergency admission encompassing the first positive SARS-CoV-2 test or within two weeks of positive outpatient testing was defined as the index admission. For this analysis, patients with no available creatinine data and patients with prior history of end stage kidney disease (ESKD) were excluded. Follow-up data were available up to 1 st December 2020.

AKI was defined and severity staged using the Kidney disease Improving Global Outcomes (KDIGO) creatinine criteria, namely an acute ≥0.3mg/dl rise in serum creatinine within a 48h window or a ≥1.5 fold increase in creatinine above pre-morbid baseline value (21) . Baseline creatinine was set using the median result from all available blood tests in the 7 to 365 days before admission. If no prior results were available, baseline creatinine was imputed based on an eGFR of 75ml/min/1.72m 2 or admission creatinine, whichever was lower. Early AKI was defined as AKI criteria being met within the first 7 days of hospital admission. In patients who survived to day 7, early AKI was further subdivided based on trajectory during admission: Recovered (absence of AKI criteria by day 7 and no further AKI); Relapsed (absence of AKI criteria by day 7, but subsequent re-occurrence of AKI later in admission);

and Persistent (persistence of AKI criteria at day 7 or requirement for RRT). Late AKI was defined as AKI occurring only after day 7. Ethnicity was defined using the NHS ethnic category codes. Relative measures of socioeconomic deprivation were assessed using the English Indices of Deprivation 2020 by matching patient postcode to national index of multiple deprivation (IMD) divided into quintiles within our study population (22) . Baseline comorbid diseases and Hospital Frailty Risk Score (HFRS) were identified by mapping to ICD-10 coding (23, 24) . Pre-existing chronic kidney disease (CKD) defined as baseline eGFR below 60ml/min/1·72m 2 was calculated using the last creatinine value available from results earlier than 7 days before hospitalisation using the CKDEpi formula (25) . ESKD was defined by ICD-10 coding (26) . Rockwood Clinical Frailty Scoring (RFS) was assessed by the admitting medical team and recorded in the electronic medical records (27) . The median CRP value for the cohort was used to a cut-off for high and low groups. Full definitions of AKI categories and baseline variables are detailed in the online supplement.

The primary outcome was survival to 30-days from time of index COVID-19 hospital admission. We assessed the composite outcome of death, new dialysis, and worsened renal function constituting the major adverse kidney event (MAKE) outcome at 90 days (MAKE90) as a secondary outcome (28) . In 90-day survivors worsened renal function was defined as eGFR <70% of baseline using the last serum creatinine value before 90 days. Other secondary endpoints were 90-day survival, ICU admission, ICU length of stay, duration of organ support on ICU, need for mechanical ventilation, ICU and hospital length of stay, and discharge destination if discharged alive from hospital.

A prospective statistical analysis plan was developed (29) . Baseline characteristics are presented as mean and standard deviation, median and interquartile range, or number and percentage, as appropriate. We compared proportions using Pearson's Chi-square test or

Fisher's exact test and continuous variables using 2-sample t-test or Wilcoxon rank-sum or signed rank (for paired data) tests, as appropriate. Multivariable logistic regression was carried out to assess risk factors for development of early AKI. Cox proportional hazards models were used to assess survival comparing AKI to no AKI adjusted for age and sex. A further multivariable Cox model was developed to assess the effect of pre-defined risk factors described associated with adverse outcomes in COVID19: ethnicity, IMD quintile, smoking status, body mass index (BMI), diabetes, hypertension (HTN), and CKD. We assessed the effects of an interaction between ethnicity and early AKI on 30-day survival.

Logistic regression modelling for the association between early AKI and ICU admission, as well as treatment using mechanical ventilation and RRT were carried out. Survival at 90-days comparing trajectory of AKI was assessed using logistic regression as relapsed-and late-AKI are not baseline hazards. Effect measures are presented as hazard ratios (HR) or odds ratios (OR) with 95% confidence intervals (CI). All analyses were performed using R version 4.0.2 (R Core Team 2020).

Subgroup analyses were carried out including only patients with known baseline creatinine.

STROBE reporting guidelines were followed (Table S1 ). A total of 1996 patients were included in our cohort, 28 without creatinine results available during their admission and 113 with pre-existing ESKD were excluded from analyses ( Figure S1) 

Of 333 patients who developed early AKI and still alive at day 7 after admission: 134 (40.2%) recovered, 47 (14.1%) relapsed, and 152 (45.6%) had persistent AKI at day 7. A total of 105 (8.2%) patients who did not have early AKI and still alive at day 7 developed late AKI after this timepoint. Baseline characteristics are presented in Table S3 . Patients with persistent or relapsed trajectories were younger (median age 65 years persistent, 72 relapsed, 74 recovered). Compared to other ethnic groups, a greater proportion of Asian patients with early AKI had persistent or relapsed AKI than recovered ( Figure S6 ). Patients with persistent or relapsed AKI had higher CRP values (median 330.0 mg/L persistent, 199.0 relapsed, 179.0 recovered). Baseline risk factors for early AKI were also more frequent in patients with late compared to no AKI. In multivariable logistic regression, survival to 90 days was worst for persistent AKI (OR 7.57 [4.50-12.89], p<0.001) ( Figure S7 ).

There was no clear evidence for any interaction between ethnicity and early AKI on 30 Associations with survival were similar although in these analyses, the risk of death associated with AKI stage 2 was comparatively greater.

In our cohort of first wave hospitalised patients, one in four COVID-19 patients developed early AKI and a further 8% developed late AKI. Over a third of early AKI cases were of stage 3 severity using KDIGO grading. Importantly, adverse outcomes were strongly associated with increased severity and persistence of AKI. The majority of early AKI was persistent meaning 45.6% of early AKI patients surviving to day 7 fulfilled criteria for acute kidney disease (AKD) by the continued presence of a serum creatinine ≥1.5 fold baseline or need for RRT (21) . Importantly, persistent AKI was most strongly associated with ongoing risk of death. In addition, after day 7, relapsed AKI after initial recovery and late AKI were both associated with worse outcomes compared to recovered early AKI.

Rates of early COVID associated AKI in this study are similar to previous studies in Europe and the US (8, 15, 30) . As in many previous studies early AKI was associated with poorer short-term survival (7, (30) (31) (32) , however severity and duration of AKI are clearly interlinked with aspects of the underlying COVID-19 disease process. This supports a comparative study of COVID-19 and non-COVID-19 hospitalised patients which demonstrated a higher incidence of AKI and a disproportionate burden of severe AKI in COVID-19 patients (33) .

Baseline risk factors for early AKI such as older age, male sex, and diabetes in this study support those of previous studies for both COVID-19 and non-COVID-19 AKI (1, 11, 15, 34) . However, we found that different demographic and comorbidity profiles were associated with higher risk of COVID-19 AKI. In particular male sex and diabetes were associated with greater adjusted-risk, suggesting that AKI could be a complication partially mediating risk of death in these subgroups previously identified as of higher risk of death in COVID-19 disease. We also demonstrate that patients of Black ethnicity were at higher risk of developing AKI and more severe AKI shown in other cohorts, this may be linked to a higher prevalence of CKD in black populations as this association disappeared in favour of CKD when only patients with known baseline creatinine were considered (9) . Similarly, more persistent or relapsing AKI trajectories were also seen in Asian patients who developed early AKI, reflecting a less benign course of AKI in this group. Furthermore, the prevalence of diabetes and CKD were significantly greater at younger ages in Asian and Black patients respectively, potentially increasing risk of AKI in these populations. These observations suggests that patients of Black and Asian backgrounds could in part be at greater risk of death in COVID-19 disease due to greater prevalence of measured and unmeasured risk factors for development and progression of AKI.

Our finding that high CRP values were associated with development, greater severity, and worse trajectories of AKI supports hypotheses underlying hyperinflammatory and cytokine release syndrome mediated damage to kidneys in COVID-19 (9, 14) . Some of this dysregulated immune response may be mediated through lung-kidney cross-talk and associations with other markers of systemic disease such as ferritin, d-dimer, and measures of severity of pulmonary disease could help elucidate pathophysiological mechanisms involved (35) . Of particular importance would be if these processes were modifiable through management strategies such as lung protective ventilation (15) .

As the impact of COVID-19 continues with surges of cases, limited hospital resources including dialysis availability need to be taken into consideration. Identifying and classifying AKI by timing and trajectory may help in tailoring patient-monitoring, initiation of AKI-prevention and treatment strategies and timely consideration of patients who will benefit from RRT (30, 31).

Little is known currently about long-term outcomes and kidney recovery after COVID-19 AKI, with only a small number of studies reporting post-hospital outcome (36) . Reported recovery of kidney function and dependence on RRT following hospital admission has been variable, with recovery at 41% to 65% and RRT dependence at 8% to 33% (37) (38) (39) . While the majority of patients in our study who received RRT and survived recovered independent kidney function, and the number of patients with worsened kidney function at follow-up was small, assessment of kidney function in COVID-19 survivors is likely to be complex. In individual patients there was considerable variability in serum creatinine at follow-up, with some, both with and without early AKI, developing new significantly elevated creatinine compared to baseline. Conversely many other patients, in all AKI categories, had creatinine levels substantially lower than baseline both at hospital discharge and afterwards. This suggests that both worsened renal function and substantial loss of muscle mass (and creatinine generation) may be occurring in COVID-19 survivors potentially confounding assessment of kidney function by serum creatinine in COVID-19 survivors. Longer-term follow-up is required to better understand recovery mechanisms for COVID-19 AKI which may differ from other forms of AKI (30) . This may require methods for assessing renal function less confounded by the effects of prolonged major illness, such as cystatin-c (40) .

This study comprises a comprehensive analysis of the epidemiology and timing of COVID-19 associated AKI in a large and ethnically diverse urban population. The detailed dataset allowed inclusion of multiple demographic and baseline risk factors into multivariable analyses. However, more data on differences in clinical management, medication use including pre-existing renin-angiotensin system (RAS) blockade, ventilation, and haemodynamic parameters could help to identify specific AKI causes. The follow-up period was longer compared to the majority of previous reports, however, important long-term outcomes such as development and progression of CKD and ESKD over the following years

are not yet available. Definitions of AKI were based only on biochemistry results and there was no data on urine output or other markers of kidney health including proteinuria.

Furthermore, imputation of baseline creatinine values was required for 675 (36.4%) patients lacking pre-admission results, however this was a much smaller proportion compared to many other AKI studies and we carried out a sensitivity analysis excluding those with unknown baseline. Finally, while AKI is associated with adverse outcomes and we hypothesise that it could be an important pathway in mediating risk of death and severity of illness in COVID-19 disease, the direction of causality in these associations cannot be proven in an observational study.

Characterisation of COVID-19 AKI by timing and trajectory could help risk stratification and target monitoring, prevention and treatment strategies. This study highlights continued need for vigilance and monitoring of AKI throughout all stages of COVID disease, especially in subgroups with higher risk of death in COVID-19 disease. Finally, longer-term follow-up and better understanding of kidney recovery after COVID-19 is warranted as outcomes are currently unclear.

No funding was received for conducting this study.

All authors have completed the ICMJE uniform disclosure form and have no relevant financial or non-financial interests associated with the submitted work to disclose. The results presented in this paper have not been published previously in whole or part, except in abstract form.

The statistical analysis plan can be accessed online. The authors will be happy to consider additional analyses of the anonymised dataset on request. The need for stringent measures to prevent re-identification of individuals within a discrete geographical location and limited time-period however preclude sharing of patient level dataset in a GDPR compliant form. 

Study approval was obtained from the Health Research Authority and protocols reviewed by the Research Ethics committee. No patient level consent was required for this study as it involved the aggregated analysis of an anonymised dataset collated by members of the direct care team. Table 1 . Cohort baseline characteristics grouped by early AKI status, n (%) unless otherwise stated. Total n=1,855 unless otherwise stated. P values based on Chi-square (for categorical) or Kruskal-Wallis test (for continuous) comparing early AKI all or by stage to no early AKI. SD: standard deviation, IQR: interquartile range, IMD: index of multiple deprivation, CKD: chronic kidney disease, HTN: hypertension, COPD: chronic obstructive pulmonary disease, CRP: C-reactive protein, ICU: intensive care unit, RRT: renal replacement therapy. 

Acute Kidney Injury in Patients with the Coronavirus Disease 2019: A Multicenter Study

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

COVID-19 and the kidney: what we think we know so far and what we don't

Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis

Acute kidney injury in critically ill patients with COVID-19

Acute kidney injury in patients hospitalized with COVID

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Kidney disease is associated with in-hospital death of patients with COVID-19

Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China

Collapsing Glomerulopathy in a Patient With COVID-19

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Management of acute kidney injury in patients with COVID-19

Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study

Postmortem Kidney Pathology Findings in Patients with COVID-19

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Explaining the racial difference in AKI incidence

Ethnicity and outcomes in patients hospitalised with COVID-19 infection in East London: an observational cohort study. medRxiv: 2020

KDIGO clinical practice guidelines for acute kidney injury

Office for National Statistics (ONS)

Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study

Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data

A new equation to estimate glomerular filtration rate

Clinical Code List -ICD-10 -End-Stage Renal Disease

A global clinical measure of fitness and frailty in elderly people

Clinical trial endpoints in acute kidney injury

Acute Kidney Injury in COVID-19: secondary analysis of prospective data from the EthICAL study

COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup

Acute Kidney Injury in the 2019 Novel Coronavirus Disease

AKI in Hospitalized Patients with and without COVID-19: A Comparison Study

Acute kidney injury

Lung-kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup

Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia

High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy

AKI in Hospitalized Patients with COVID-19

AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19

Superiority of Serum Cystatin C Over Creatinine in Prediction of Long-Term Prognosis at Discharge From ICU

 Tables   Table 1. Baseline characteristic table by